S&P 500   3,963.51 (+0.75%)
DOW   33,781.48 (+0.55%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
S&P 500   3,963.51 (+0.75%)
DOW   33,781.48 (+0.55%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
S&P 500   3,963.51 (+0.75%)
DOW   33,781.48 (+0.55%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
S&P 500   3,963.51 (+0.75%)
DOW   33,781.48 (+0.55%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
OTCMKTS:BRTX

BioRestorative Therapies - BRTX Stock Forecast, Price & News

$3.02
+0.09 (+3.07%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.93
$3.35
50-Day Range
$2.58
$3.68
52-Week Range
$2.46
$6.25
Volume
18,805 shs
Average Volume
42,413 shs
Market Capitalization
$11.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BRTX stock logo

About BioRestorative Therapies (OTCMKTS:BRTX) Stock

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

BRTX Stock News Headlines

Best Online Therapy Of 2022
Major Catalyst Near Term
BioRestorative Therapies, Inc. (BRTX)
See More Headlines
Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

BRTX Company Calendar

Today
12/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BRTX
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Net Income
$-44,300,000.00
Net Margins
-28,538.84%
Pretax Margin
-28,553.72%

Debt

Sales & Book Value

Annual Sales
$50,000.00
Book Value
$6.18 per share

Miscellaneous

Free Float
3,006,000
Market Cap
$11.02 million
Optionable
Not Optionable
Beta
63.89

Key Executives

  • Mr. Lance  AlstodtMr. Lance Alstodt (Age 51)
    Chairman, Pres & CEO
    Comp: $275k
  • Mr. Francisco J. Silva (Age 47)
    Chief Scientist, VP of R&D, Sec. and Director
    Comp: $259.38k
  • Mr. Robert Eugene Kristal (Age 54)
    Chief Financial Officer
  • Mr. Robert Paccasassi (Age 53)
    VP of Quality Assurance & Regulatory Compliance
  • Dr. Wayne J. Olan M.D.
    Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board













BRTX Stock - Frequently Asked Questions

Should I buy or sell BioRestorative Therapies stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioRestorative Therapies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BRTX shares.
View BRTX analyst ratings
or view top-rated stocks.

How have BRTX shares performed in 2022?

BioRestorative Therapies' stock was trading at $4.34 at the start of the year. Since then, BRTX shares have decreased by 32.5% and is now trading at $2.93.
View the best growth stocks for 2022 here
.

When did BioRestorative Therapies' stock split?

BioRestorative Therapies's stock reverse split on the morning of Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

What other stocks do shareholders of BioRestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include Co-Diagnostics (CODX), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), iBio (IBIO), Inovio Pharmaceuticals (INO), PharmaCyte Biotech (PMCB), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), Inpixon (INPX) and OPKO Health (OPK).

What is BioRestorative Therapies' stock symbol?

BioRestorative Therapies trades on the OTCMKTS under the ticker symbol "BRTX."

How do I buy shares of BioRestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioRestorative Therapies' stock price today?

One share of BRTX stock can currently be purchased for approximately $2.93.

How much money does BioRestorative Therapies make?

BioRestorative Therapies (OTCMKTS:BRTX) has a market capitalization of $10.69 million and generates $50,000.00 in revenue each year.

How can I contact BioRestorative Therapies?

BioRestorative Therapies' mailing address is 40 MARCUS DRIVE, MELVILLE NY, 11747. The official website for the company is www.biorestorative.com. The company can be reached via phone at (631) 760-8100 or via email at ir@biorestorative.com.

This page (OTCMKTS:BRTX) was last updated on 12/8/2022 by MarketBeat.com Staff